| Abstract |
Objective To analyze the effects of citalopram treatment on depression, negative depression, cognitive function and hypothalamic-pituitary-adrenalin function (HPA) in patients with post-stroke depression. Methods Ninety-seven patients with post-stroke depression who were admitted to our hospital from January 2017 to June 2018 were randomly divided into the control group (n=48) and the observation group (n=49). The control group received routine symptomatic cerebrovascular disease. In the rehabilitation group, the patients in the observation group were treated with citalopram orally. The patients in both groups were treated for 8 weeks. The hypothalamic-pituitary-adrenalin function, neurological function, cognitive function, serum cytokines and depression were observed. And compare clinical efficacy and safety. Results The levels of TNF-α, IL-6, IL-2, Cor, CRH, ACTH, Hcy, neurological function and HAMD were lower in the observation group than in the control group. The MoCA score and total effective rate were higher than those in the control group (P<0.05). The TESS score was not statistically significant (P>0.05). Conclusion Citalopram can effectively improve HPA axis function in patients with post-stroke depression, regulate serum cytokine levels, alleviate negative emotions, promote neurological function and cognitive function recovery, and have high safety.
|